Heterozygous pathogenic variants in POMC are not responsible for monogenic obesity: Implication for MC4R agonist use
GATTA-CHERIFI, Blandine
Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
< Réduire
Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
Langue
EN
Article de revue
Ce document a été publié dans
Genetics in Medicine. 2023-07, vol. 25, n° 7
Résumé en anglais
Purpose: Recessive deficiency of proopiomelanocortin (POMC) causes childhood-onset severe obesity. Cases can now benefit from the melanocortin 4 receptor agonist setmelanotide. Furthermore, a phase 3 clinical trial is ...Lire la suite >
Purpose: Recessive deficiency of proopiomelanocortin (POMC) causes childhood-onset severe obesity. Cases can now benefit from the melanocortin 4 receptor agonist setmelanotide. Furthermore, a phase 3 clinical trial is evaluating setmelanotide in heterozygotes for POMC. We performed a large-scale genetic analysis to assess the effect of heterozygous, pathogenic POMC variants on obesity. Methods: A genetic analysis was performed in a family including 2 cousins with childhood-onset obesity. We analyzed the obesity status of heterozygotes for pathogenic POMC variants in the Human Gene Mutation Database. The association between heterozygous pathogenic POMC variants and obesity risk was assessed using 190,000 exome samples from UK Biobank. Results: The 2 cousins carried a compound heterozygous pathogenic variant in POMC. Six siblings were heterozygotes; only 1 of them had obesity. In Human Gene Mutation Database, we identified 60 heterozygotes for pathogenic POMC variants, of whom 14 had obesity. In UK Biobank, heterozygous pathogenic POMC variants were not associated with obesity risk, but they modestly increased body mass index levels. Conclusion: Heterozygous pathogenic POMC variants do not contribute to monogenic obesity, but they slightly increase body mass index. Setmelanotide use in patients with obesity, which would only be based on the presence of a heterozygous POMC variant, can be questioned. © 2023 American College of Medical Genetics and Genomics< Réduire
Mots clés
Heterozygous
Hypocortisolism
Obesity
POMC
Variant
Projet Européen
European Union (FEDER)
Project ANR
EGID Diabetes Pole
Plate forme Lilloise de séquençage du génome humain pour une médecine personnalisée
PreciDIAB Institute, the holistic approach of personal diabets care
Organisation et montée en puissance d'une Infrastructure Nationale de Génomique
Plate forme Lilloise de séquençage du génome humain pour une médecine personnalisée
PreciDIAB Institute, the holistic approach of personal diabets care
Organisation et montée en puissance d'une Infrastructure Nationale de Génomique
Unités de recherche